Research has shown that IL-7 and IL-12 play critical roles in maintaining lymphocyte homeostasis and have been suggested to reverse lymphopenia and improve the clinical outcomes of cancer patients, and recent studies showed that intratumoral dual expression of IL-7 and IL-12 increased activated CD8+ T cells in poorly immunogenic tumors [24–26]. The gene discussed is CD8A; the disease is lymphopenia.